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who suffered a VTE event and those that did not. Risk adjustment was done using 
propensity score matching (using the ProbChoiceTM algorithm) controlling for baseline 
demographic and clinical characteristics between patients with and without VTE. 
RESULTS: In patients who underwent hip fracture surgery (n = 104,952), 1.9% had 
post-operative VTE events during their initial hospitalization. Almost 69% (n = 1377) 
of these patients suffered deep vein thrombosis (DVT), 25% (n = 501) had a pulmo-
nary embolism (PE), and 6% (n = 119) had both DVT and PE. After multivariate 
adjustment for pre-speciﬁed covariates, mortality was almost 50% higher for patients 
with VTE compared to those without VTE. Differences in mortality rate were more 
pronounced for PE patients, whom the event was associated with almost two-fold. 
The VTE group was more likely to be re-hospitalized in one year (odds ratio: 1.44, p 
= 0.02). Bleeding was 2.26 times higher (p = 0.000). CONCLUSIONS: VTE events 
during initial hospitalization for hip fracture surgery increased the mortality, re-hos-
pitalization and bleeding compared with no VTE events.
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OBJECTIVES: To estimate re-hospitalization and bleeding rates during the 90 days 
after a venous thromboembolism (VTE) event in patients who underwent knee replace-
ment surgery and to compare the outcomes with patients who did not suffer 
VTE. METHODS: Based on 2005–2007 national Medicare claims, all patients who 
underwent knee replacement surgery were identiﬁed. The 90 days follow-up event rates 
for patients who had a VTE event during their initial hospitalization were calculated. 
Events were compared between patients who suffered a VTE event and those who did 
not. Risk adjustment was done using propensity score matching (using the ProbChoi-
ceTM algorithm) controlling for baseline demographic and clinical characteristics 
between patients with and without VTE. RESULTS: In patients who underwent total 
knee replacement surgery (n = 104,952), 1.9% had post-operative VTE events during 
their initial hospitalization. Almost 69% (n = 1377) of these patients had deep vein 
thrombosis (DVT), 25% (n = 501) had pulmonary embolism (PE), and 6% (n = 119) 
had both DVT and PE. The overall likelihood of mortality was four times higher for 
VTE patients versus those without VTE (1.35% vs. 0.35%). Patients with VTE during 
their initial hospitalization were more likely to be hospitalized in 90 days (compared to 
patients without an event during the same hospital stay (16.62% vs. 8.00%). In 90 days 
after the event, patients with VTE were more likely to have bleeding (10.17% vs. 
2.68%). CONCLUSIONS: VTE events during initial hospitalization for total knee 
replacement surgery increased the adverse events compared with no VTE events.
PCV5
ADVERSE EVENT ANALYSIS FOR MEDICARE PATIENTS WHO 
UNDERWENT HIP FRACTURE SURGERY AND SUFFERED VENOUS 
THROMBOEMBOLISM
Wang L1, Baser O2
1STATinMED Research, Ann Arbor, MI, USA, 2STATinMED Research / University of 
Michigan, Ann Arbor, MI, USA
OBJECTIVES: To estimate re-hospitalization and bleeding during the 30 days after a 
venous thromboembolism (VTE) event in patients following hip fracture surgery and 
to compare the outcomes with patients without VTE. METHODS: Based on 2005–
2007 national Medicare claims, all patients who underwent hip fracture surgery were 
identiﬁed. The 30 days follow-up event rates for patients who had a VTE event during 
their initial hospitalization were calculated. Events were compared between patients 
who suffered a VTE event and those who did not. Risk adjustment was done using 
propensity score matching controlling for baseline demographic and clinical charac-
teristics between patients with and without VTE. RESULTS: In patients who under-
went hip fracture surgery (n = 50,245), 1.5% had post-operative VTE during their 
initial hospitalization. Almost 77% (n = 573) of these patients had deep vein throm-
bosis (DVT), 20% (n = 141) had a pulmonary embolism (PE), and 3% (n = 34) had 
both DVT and PE. Patients with VTE during their initial hospitalization were more 
likely to be hospitalized in 30 days (compared to patients without an event during the 
same hospital stay (32% vs. 6.82%). In 30 days after the event, patients with VTE 
were more likely to have bleeding (10.65% vs. 0.68%). CONCLUSIONS: VTE events 
during initial hospitalization for hip fracture surgery patients increased the adverse 
events compared with no VTE events.
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OBJECTIVES: The aim of this study was to conduct a meta-analysis of randomized 
clinical trials (RCTs) to identify the effectiveness and safety of atorvastatina 
(20 mg–80 mg) against pravastatin, simvastatin and rosuvastatin. METHODS: A 
systematic review was performed including RCTs in primary and secondary preven-
tion where total cholesterol, LDL-C, HDL-C, major cardiovascular events, as well as 
adverse events frequency werw analyzed. RCTs were searched in March 2009 in 
Medline, EMBASE and the Cochrane Collaboration. Two independent reviewers 
identiﬁed the abstracts, selected the full articles, and extracted the data. Odds ratios 
(OR) and weighted means differences were calculated with 95% conﬁdence intervals 
(95%CI). Random effects models were employed in the Meta-analyses using RevMan 
v.5.0 software. RESULTS: From 7539 studies, 66 RCT were selected. Atorvastatin 
showed statistically a higher improvements in LDL-C, total cholesterol, HDL-C and 
triglycerides in comparison to pravastatin and simvastatin (5%–15%). Rosuvastatin 
was statistically superior against atorvastatin in LDL-C and total cholesterol, however 
not in HDL-C and triglycerides (p < 0.01). Atorvastatin obtained higher reductions 
in acute myocardial infarctions (AMI), unstable angina, and revascularizations in 
comparison to pravastatin and simvastatin (p < 0.05). Atorvastatin 80 mg showed in 
comparison to pravastatin 40 mg a higher reduction of mayor cardiovascular events 
(OR 0.87; 95%CI 0.77–0.97, p = 0.01), revascularization (OR 0.86; IC95% 0.76–
0.98, p = 0.02) and unstable angina (OR 0.74; 95%CI 0.57–0.95, p = 0.02); neverthe-
less no statistical differences were found for AMI or cardiovascular death. Rosuvastatin 
requires data on cardiovascular events prevention in order to be compare appropri-
ately against atorvastatin. The frequency of adverse events resulted similar among all 
the statins considered in the assessment. CONCLUSIONS: Atorvastatin in comparison 
to pravastatin and simvastatin showed a higher control of dyslipidemia and a better 
reduction of major cardiovascular events, without increasing the frequency of adverse 
events.
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OBJECTIVES: To examine incidence of and the health outcomes associated with 
potential drug-drug interactions (DDIs) between ACE/ARBs and potassium sparing 
diuretics among Medicaid patients. METHODS: A retrospective matched cohort study 
was conducted of beneﬁciaries in the Mississippi Medicaid program from January 
2002 to December 2004. Potential DDIs were deﬁned as medication possession data 
indicating an object drug (ACE/ARB) and a precipitant drug (potassium sparing 
diuretic) were taken with overlapping dates. The ﬁrst day of overlap was designated 
as the DDI index date. A 6-month washout period was used for exposures. Exposed 
patients were matched 1-1 to controls taking ACE/ARBs and assigned the same index 
date. Exact matching was done on sex, race, CHF comorbidity, and cerobrovascular 
disease comorbidity and close matching was done for age (±10) and ﬁrst use date for 
ACE/ARB (±45). Outcomes included hospitalizations and ER visits within 30 days of 
the index date and payments associated with these services. RESULTS: A total of 
68,299 patients were identiﬁed as taking ACE/ARBs during the observation period 
with 5572 (8.4%) exposed to a potential DDI. A total of 5599 exposed patients were 
matched. The effect of DDI exposure on hospitalization and ER visit rates was tested 
using SAS ﬁxed effects logistical regression while controlling for sex, age, race and 
overall Charlson comorbidity index. The point-speciﬁc odds ratio for DDI exposure 
was 1.41 (95% CI = 1.29 − 1.54) for hospitalization and 1.21 (95% CI = 1.11 − 1.31) 
for ER visits. A paired t-test was used to examine differences in Medicaid payments 
during the 30-days after the index date. Total payments were signiﬁcantly higher (p 
< 0.001) for the exposed patients ($2289) than for the control patients ($1,614). 
CONCLUSIONS: Potential ACE/ARB DDIs were a signiﬁcant problem among the 
Mississippi Medicaid patients and during the study period; potentially contributing 
more than $3.7M in additional health care costs.
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OBJECTIVES: Adverse events –Aes—due to medication errors are numerous. One 
type of error is the combination of substances with a known unwanted pharmacologi-
cal interaction. In the years 2001 to 2006 a total of 39521 AEs with ICD10 codes 
indicating drugs as reason where documented in Austrias hospitals. There is no report-
ing system or documentation for adverse events in ambulatory care. So the rate of 
AEs in the outpatient setting is unknown. One of the main projects in Austrias e-health 
roadmap is an e-medication system. Due to the foreseeable costs an estimation and 
calculation of potential beneﬁts is mandatory. METHODS: We use reimbursement 
data of the Austrian social insurance companies covering the years 2006 and 2007. 
The domains included are pharmaceutical reimbursement, reimbursement of outpa-
tient medical services, hospital reimbursement data and sick leave data. We focus on 
interactions between the following pharmaceutical groups: 1. ATC code C10AA—
statins, 2. ATC code N5BA—benzodiacepins, 3. ATC code J01FA makrolide antibiot-
ics and 4. ATC code C01BD amiodarone. RESULTS: The main question to answer 
is the prevalence and incidence of such interaction patterns. This will lead to a descrip-
tion of the epidemiology of potential AEs which can at least be qualiﬁed as medical 
errors. The second question is the frequency of clinical relevant interactions. A clinical 
(and economic) relevance is ascertained, if the interaction needs medical treatment. 
The detection of outcomes of an interaction is the main challenge. CONCLUSIONS: 
The extent to which an e-medication system can improve patient safety can be esti-
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mated. Therefore prescriptions causing interaction coming from one ofﬁce should be 
prevented. But prescriptions from different ofﬁces cannot be avoided by the use of 
this isolated solution. Only a comprehensive e-health solution summoning up medica-
tion of a patient from different sources has the potential to improve patient safety. 
There are pharmacologic interactions with different clinical relevance.
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OBJECTIVES: The aim of this study was to conduct a meta-analysis to identify the 
potential differences of cardiovascular risk factors between men and women in 
primary prevention. METHODS: A systematic review was performed identifying 
prospective cohorts studies in which cardiovascular risk factors were analyzed 
(tobacco use, hypertension, diabetes, obesity and dyslipdemia) associated to the devel-
opment of acute myocardial infarction, angina pectoris or cardiovascular death, and 
in which results were segmented between men and women. The search was done in 
October 2009 in Medline, EMBASE and the Cochrane Collaboration. Two indepen-
dent reviewers identiﬁed the abstracts, selected full articles and extracted the data. 
Relative risk(RR) with 95% conﬁdence intervals (95%CI) were calculated. Random 
effects models were employed in the meta-analyses using Meta-Analyst v.2.0 software. 
A meta-regression was also conducted. RESULTS: From 3,712 studies, 21 cohort 
studies were selected. The number of participants among the trials varied between 
5,000 and 600,000 per study with a follow-up from 5 to 40 years. The meta-analyses 
showed that premenopausal women in comparison to men had a higher risk of having 
cardiovascular event when they have diabetes mellitus (RR 2.79 vs. 2.03), obesity 
(1.62 vs. 1.41), hypercholesterolemia (1.91 vs. 1.49), increase in LDL levels (2.08 vs. 
1.72) or increase in HDL levels (2.22 vs. 1.61); however, men showed higher risk of 
cardiovascular events when they have hypertension (RR 1.771; 95%CI 1.714–1.830 
vs. RR 1.812; 95%CI 1.759–2.305). In addition, women use of contraceptives was 
not a signiﬁcant cardiovascular risk factor. CONCLUSIONS: The majority of cardio-
vascular risk factors seem to be higher in premenopausal women rather than men. 
Preventive programs should include female population in other to avoid a greater 
number of cardiovascular events in the future.
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OBJECTIVES: To evaluate 1) use of diabetes and cardiovascular medications; 2) the 
associations of medication compliance with disease burden. METHODS: California 
Medicaid administrative data (2002–2004) were used to identify patients ≥40 years 
of age with a diagnosis of type II diabetes concurrent with any combination of the 
following cardiovascular diseases (CVD): hypertension (HYPT), coronary artery 
disease (CAD), and heart failure (HF). We assessed patients use of any appropriate 
diabetes or cardiovascular medication. Proportion of days covered ≥0.8 was used to 
evaluate medication compliance. Disease burden was deﬁned as any emergency or 
inpatient visit. Logistic regressions were used to identify factors associated with disease 
burden in 2004. RESULTS: We identiﬁed 21,740 patients. Fifty-six percent of patients 
ﬁlled both diabetes and cardiovascular medications. When compared to patients with 
comorbid HYPT(51%), those with two CVD conditions HF & CAD(69%) or HYPT 
& CAD(64%) were more likely to ﬁll both diabetes and cardiovascular medications 
(P < 0.0001). Approximately 43% of patients did not ﬁll or were noncompliant with 
appropriate medications. Major signiﬁcant factors associated with disease burden 
included CVD type vs. HYPT: HF & CAD (OR:3.19), HYPT & CAD (OR:1.55), HF 
(OR:2.12), and CAD (OR:2.31); comorbidities (OR:1.94); medications used vs. no 
appropriate medication ﬁlled: ﬁlled both diabetes and cardiovascular medications 
(OR:1.75), ﬁlled only diabetes medication (OR:1.54); noncompliance with medica-
tions vs. compliance with both medications: not ﬁlled or noncompliant (OR:1.75), or 
compliance with only diabetes (OR:1.35) or only cardiovascular medication 
(OR:1.20); two or more cardiovascular medication ﬁlls (OR:1.20). CONCLUSIONS: 
Prevalence of use for both appropriate diabetes and cardiovascular medications was 
low in diabetic patients with comorbid CVD. We identiﬁed multiple risk factors of 
disease burden, primarily those related to condition severity (based on proxy measures 
of comorbidity with two CVD or ﬁlling both diabetes and CVD medications), as well 
as not using or not complying with medications.
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OBJECTIVES: The objective of this study was to explore trends in high sensitivity 
C-reactive protein (hs-CRP) screening prior to statin use, as compared to current lipid 
screening practices. METHODS: The PharMetrics Integrated Outcomes Database was 
used to obtain medical claims records for continuously enrolled adult (≥18 years) 
ﬁrst-time statin users. Patients were followed for one year. Both hs-CRP and lipid tests 
were identiﬁed by CPT-4 procedure codes. Descriptive statistics were used to charac-
terize the population and estimate unadjusted associations between patient character-
istics and hs-CRP testing. Multivariable logistic regression was used to estimate the 
odds of testing, controlling for age, gender, diabetes, statin intensity, prescribing physi-
cian specialty, geographic region and health plan type. RESULTS: Between July 1, 
1997 and March 31, 2007, 33,666 new statin users received lipid tests within 90 days 
prior to the index statin prescription. One thousand (3%) also received hs-CRP tests 
during this time. Over 80% of these individuals received the tests in 2004 or later. 
Those receiving hs-CRP tests were less likely to have a Medicare, Medicaid or other 
type of plan, as compared to private insurance (P < .05) and were less likely to reside 
in the South, Midwest or West, as compared to the Northeast (P < 0.01). Individuals 
who received hs-CRP tests had higher adjusted odds of receiving a high potency statin 
(OR = 1.37, P < .01) and lower odds of having diabetes (OR = 0.56, P < 0.01). Those 
receiving hs-CRP tests were more likely to have a cardiologist as their statin-prescrib-
ing physician, rather than a family or general practitioner (OR = 1.31, P = 0.02). 
CONCLUSIONS: Rates of hs-CRP testing are very low, but higher among those seeing 
a cardiologist or having private insurance. Those who received a high potency statin 
had higher rates of testing, suggesting that those with higher cardiovascular risk may 
be more likely to receive an hs-CRP test.
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OBJECTIVES: Antithrombotic therapy is effective in preventing thromboembolic 
diseases, and it has been recommended by several international guidelines to prevent 
deep vein thrombosis (DVT) after major orthopedic surgeries under carefully monitor-
ing bleeding risks. To establish Taiwanese local guidance, this case study aims to 
evaluate the current utilization and effectiveness of antithrombotic agents for prevent-
ing DVT after total hip replacement (THR). METHODS: This one-year retrospective 
cohort study was conducted at a medical center in Southern Taiwan from May 2008 
to April 2009. Adult patients (above 18 years) who had undergone primary THR were 
identiﬁed by inpatient electronic database. Their medical records were reviewed from 
surgery date to three months post-operation for collecting demographic details and 
DVT-related clinical symptoms as the surrogate of effectiveness. Descriptive statistic 
and time-to-event analysis were then conducted. RESULTS: Medical records of 82 
patients (57.32% women) were reviewed. The average age is 59.15 ± 13.43 years and 
the mean body mass index is 25.20 ± 4.86 kg/m2. Only 31 out of the 82 patients 
(37.80%) had ever received prophylactic antithrombotic agents after surgery and all 
of them used aspirin, but only 22 patients used aspirin for more than 10 days. Twelve 
patients presented DVT symptoms after surgery but only one is from prophylactic 
group. Independent relative risk of DVT for patients without prophylaxis is 8.25 folds 
of patients with prophylaxis (95% conﬁdence interval: 1.48, 154.91). DVT symptoms 
mainly (91.67%) occurred within 15 days after THR and the median duration to 
symptoms presentation is 12 days. CONCLUSIONS: Antithrombotic therapy is not 
commonly used to prevent DVT after THR in this medical center. Aspirin alone seems 
effectively reduces the risk of DVT-related symptoms. It is necessary to further inves-
tigate the effectiveness of prophylactic antithrombotic agents after THR from Taiwan-
ese population-based database and explore the potential genetic factors inﬂuencing 
the effectiveness of antithrombotic therapy.
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OBJECTIVES: Comparative effectiveness research identiﬁes superior clinical devices 
or treatments through head-to-head comparisons. This study describes the use of an 
innovative framework to assess the quality and safety of two INR Point of Care 
devices. METHODS: Patients enrolled in the hematology Anticoagulation Manage-
ment Service provided three INR measures: one venous sample analyzed by our lab 
(considered the standard measure), one ﬁngerstick analyzed by the Hemochron Sig-
nature Elite POC device and another ﬁngerstick by the Coaguchek XS Plus. Agreement 
between INR values from each device and the lab was assessed. Agreement was 
achieved when the INR measures were predicted by a novel, validated method to lead 
to the same clinical decision. Differences in agreement between the POC devices and 
the lab were assessed using McNemar’s test of paired proportions. RESULTS: Ninety-
nine subjects were enrolled into the study. There was signiﬁcantly less difference 
between INR values from the Coaguchek XS device and the lab compared to the 
Hemochron device (average absolute difference = 0.24 vs 0.41 p < 0.05). The Hemo-
chron device tended to report both high and low INR values were within the target 
range when the laboratory said otherwise. Consequently, the Hemochron device was 
signiﬁcantly more likely to lead to a different clinical decision than the core laboratory 
compared to the Coaguchek XS (30% vs. 18%, respectively; RR: 1.7, 95% CI: 1.1–
2.4, P = 0.007). CONCLUSIONS: Comparative effectiveness analysis can provide 
essential information to make informed decisions when selecting medical devices to 
